Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Spermosens AB ("Spermosens" or the "Company") today announces that the patent "Biosensor for Male Infertility" (MX/a/2021/002145) has been granted in Mexico. The patent covers the company's unique method for measuring sperm binding to the egg, a critical biological interaction during fertilization that no existing test can evaluate.
The patent granted in Mexico strengthens Spermosens' intellectual property portfolio, which already includes granted patents in key markets including Europe, United States of America, Canada, Japan, South Korea, Australia, South Africa, Hong Kong and Singapore. The protection covers both the method and system underlying the JUNO-Checked technology, providing long-term exclusivity for the company's approach to assessing critical sperm function.
Tore Duvold, CEO of Spermosens, comments: "I am very pleased that our patent for JUNO-Checked has been granted in Mexico, a significant and growing market for innovative fertility diagnostics. The granted patent in Mexico is expanding our global IP position for JUNO-Checked."
About JUNO-Checked
JUNO-Checked is a patented diagnostic technology developed by Spermosens to assess the ability of sperm cells to bind to the JUNO receptor on the egg - a crucial step in fertilization. This interaction cannot be evaluated with conventional semen analysis. By replicating this process in vitro, JUNO-Checked provides a direct, functional measurement of sperm-egg binding, offering new insight for the assessment of male fertility.
About the Mexican market
Infertility affects a significant number of couples in Mexico, with male factors contributing to a substantial share of cases. The country's fertility services market is growing steadily, supported by increasing awareness, advancing clinic infrastructure, and broader access to treatment. According to Grand View Research, the Mexican fertility services market generated approximately USD 452 million in 2023 and is projected to reach around USD 855 million by 2030.
References
- Grand View Research - Mexico Fertility Services Market Report:
https://www.grandviewresearch.com/industry-analysis/mexico-fertility-services-marke - WHO - Infertility Fact Sheet:
https://www.who.int/news-room/fact-sheets/detail/infertility - The Lancet - Male infertility overview (Agarwal et al., 2021):
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32667-5/fulltext
For further information, please contact:
Tore Duvold, CEO
Email: info@spermosens.com
Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science-driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision in evaluations by measuring sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatment strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.